Abstract: Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients’ quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.

Keywords: age, cisplatin, comorbidities, contraindication, frailty, toxicity


中文翻译：

---

伊比利亚-美洲关于无法接受顺铂治疗的头颈鳞状细胞癌患者的专家共识：临床实践建议


摘要：顺铂是头颈鳞状细胞癌 (SCCHN) 的治疗标准，无论是与高剂量放疗联合治疗局部晚期疾病，还是与其他药物联合治疗转移性/复发性疾病，均已显示出疗效。然而，与顺铂相关的常见毒性，如神经毒性、肾毒性、耳毒性和血液毒性，尤其是高剂量给药时，对患者的生活质量具有重要影响。给予顺铂的决定取决于多个患者因素，例如年龄、体能状态、体重减轻、合并症、既往毒性、慢性病毒感染，甚至当前的 SARS-CoV-2 大流行。为了制定 SCCHN 患者的治疗建议，来自西班牙和拉丁美洲的医学和放射肿瘤学专家小组讨论了如何识别不适合接受顺铂的患者，为他们提供最合适的治疗方案。


关键词：年龄、顺铂、合并症、禁忌症、虚弱、毒性